Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | USP30 | Q70CQ3 | 5/20 | 0.40 |
| ▸ | UCHL1 | P09936 | 2/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15855803 | 1.00 | HSD17B10 (0.46) | HSD17B10SMN1; SMN2NPC1USP30UCHL1 | |
| SCHEMBL489823 | 0.90 | HSD17B10 (0.57) | HSD17B10SMN1; SMN2NPC1USP30UCHL1 | |
| SCHEMBL2492664 | 0.89 | HSD17B10 (0.52) | HSD17B10SMN1; SMN2NPC1USP30UCHL1 | |
| SCHEMBL5427853 | 0.89 | HSD17B10 (0.52) | HSD17B10SMN1; SMN2NPC1USP30UCHL1 | |
| SCHEMBL5427850 | 0.89 | HSD17B10 (0.52) | HSD17B10SMN1; SMN2NPC1USP30UCHL1 | |
| SCHEMBL444365 | 0.86 | HSD17B10 (0.43) | HSD17B10SMN1; SMN2NPC1USP30UCHL1 | |
| SCHEMBL2096289 | 0.86 | HSD17B10 (0.43) | HSD17B10SMN1; SMN2NPC1USP30UCHL1 | |
| SCHEMBL25701906 | 0.86 | HSD17B10 (0.43) | HSD17B10SMN1; SMN2NPC1USP30UCHL1 | |
| SCHEMBL1648324 | 0.83 | HSD17B10 (0.43) | HSD17B10SMN1; SMN2NPC1USP30UCHL1 | |
| SCHEMBL16637180 | 0.81 | USP30 (0.42) | HSD17B10SMN1; SMN2USP30LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8030499-B2 | 1,3-dihydro-2H-indole-2-one compound and pyrrolidine-2-one compound fused with aromatic heterocycle | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2011-10-04 | — | — | US | disclosed |
| US-20080318923-A1 | 1,3-Dihydro-2H-Indole-2-One Compound and Pyrrolidine-2-One Compound Fused With Aromatic Heterocycle | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2008-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080318923-A1 | 1,3-Dihydro-2H-Indole-2-One Compound and Pyrrolidine-2-One Compound Fused With Aromatic Heterocycle | AVPR1B, AVPR1A, AVPR2 | HSD17B10 588/4885SMN1; SMN2 2982/4885NPC1 990/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.